Promising option in the prevention of idiopathic anaphylaxis: Omalizumab

Anaphylaxis is a serious and probably lethal systemic reaction which occurs instantaneously after exposure to an allergen. It can occur after exposure to various triggers including allergic and non‐allergic factors. When a trigger cannot be determined, idiopathic anaphylaxis is considered. In idiopa...

Full description

Saved in:
Bibliographic Details
Published in:Journal of dermatology 2012-06, Vol.39 (6), p.552-554
Main Authors: DEMIRTÜRK, Mustafa, GELINCIK, Asli, ÇOLAKOĞLU, Bahattin, DAL, Murat, BÜYÜKÖZTÜRK, Suna
Format: Article
Language:English
Subjects:
Allergens
Allergies
Anaphylaxis
Anaphylaxis - etiology
Anaphylaxis - prevention & control
Anti-Allergic Agents - administration & dosage
Antibodies, Anti-Idiotypic - administration & dosage
Antibodies, Monoclonal, Humanized - administration & dosage
Antihistamines
anti‐immunoglobulin E
Asthma
Asthma - therapy
Drug Administration Schedule
Drugs
Female
Humans
idiopathic anaphylaxis
Immunoglobulin E
Middle Aged
Monoclonal antibodies
Omalizumab
Pain
Pharynx
Prophylaxis
Steroid hormones
Urticaria
Urticaria - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Anaphylaxis is a serious and probably lethal systemic reaction which occurs instantaneously after exposure to an allergen. It can occur after exposure to various triggers including allergic and non‐allergic factors. When a trigger cannot be determined, idiopathic anaphylaxis is considered. In idiopathic anaphylaxis presenting with frequent attacks, long‐term prophylaxis with H1 antihistamine and steroid treatment are recommended. Omalizumab, a humanized monoclonal antibody drug which decreases free immunoglobulin E molecules in the circulation, is approved for the treatment of chronic severe persistent allergic asthma. We report a 46‐year‐old female patient with severe uncontrolled allergic asthma and idiopathic anaphylaxis presenting with attacks of abdominal pain, generalized urticaria, feeling of strangulation in her throat and unconsciousness. Omalizumab at a dose of 375 mg once every 2 weeks was administrated and at the end of 3 months anaphylactic attacks had ceased. At the end of the sixth month of omalizumab therapy, her injection intervals were extended to 4 weeks. After she began experiencing moderate attacks of urticaria and hoarsening, however, initial treatment plan was reestablished. Currently, she has completed her first year of treatment without further attacks.
ISSN:0385-2407
1346-8138
DOI:10.1111/j.1346-8138.2012.01520.x